Autonomix Approved Of Protocol Amendment By Ethics Committee Upon Completion Of All Lead-In Patients In Ongoing Human Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Autonomix has received approval from the Ethics Committee for a protocol amendment in its ongoing human clinical trial. The company plans to release topline results from the 'lead-in' patients (n=5) imminently.
June 03, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Autonomix has received Ethics Committee approval for a protocol amendment in its ongoing clinical trial and will soon release topline results from the 'lead-in' patients.
The approval of the protocol amendment and the imminent release of topline results from the 'lead-in' patients are positive developments. These could potentially lead to favorable outcomes in the clinical trial, boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100